IT1237792B - Composti attivi come inibitori dell'enzima hmg-coa reduttasi - Google Patents

Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Info

Publication number
IT1237792B
IT1237792B IT02276789A IT2276789A IT1237792B IT 1237792 B IT1237792 B IT 1237792B IT 02276789 A IT02276789 A IT 02276789A IT 2276789 A IT2276789 A IT 2276789A IT 1237792 B IT1237792 B IT 1237792B
Authority
IT
Italy
Prior art keywords
hmg
inhibitors
active compounds
coa reductase
reductase enzyme
Prior art date
Application number
IT02276789A
Other languages
English (en)
Other versions
IT8922767A0 (it
Inventor
Giorgio Bertolini
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT02276789A priority Critical patent/IT1237792B/it
Publication of IT8922767A0 publication Critical patent/IT8922767A0/it
Priority to EP90123759A priority patent/EP0436851A1/en
Priority to JP2418292A priority patent/JPH04208266A/ja
Application granted granted Critical
Publication of IT1237792B publication Critical patent/IT1237792B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
IT02276789A 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi IT1237792B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT02276789A IT1237792B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EP90123759A EP0436851A1 (en) 1989-12-21 1990-12-11 Compounds active as inhibitors of the enzyme HMG-CoA reductase and pharmaceutical compositions containing them
JP2418292A JPH04208266A (ja) 1989-12-21 1990-12-20 酵素ＨＭＧ−ＣｏＡレダクターゼの抑制剤として活性な化合物ならびに該化合物を含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02276789A IT1237792B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Publications (2)

Publication Number Publication Date
IT8922767A0 IT8922767A0 (it) 1989-12-21
IT1237792B true IT1237792B (it) 1993-06-17

Family

ID=11200235

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02276789A IT1237792B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Country Status (3)

Country Link
EP (1) EP0436851A1 (it)
JP (1) JPH04208266A (it)
IT (1) IT1237792B (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322942A (en) * 1991-06-03 1994-06-21 Regents Of The University Of California Synthesis of optically active lactones from L-aspartic acid and intermediates thereof
SK792004A3 (sk) * 2001-07-06 2005-03-04 Teva Pharmaceutical Industries Ltd. Syntéza a medziprodukty derivátov 3,5-dihydroxyheptánovej kyseliny
PT1404642E (pt) * 2001-07-06 2010-03-29 Basf Se Processo para a preparação de derivados do ácido 7-amino sin 3,5-dihidroxi heptanoico, intermediários respectivos e métodos para a sua preparação
MXPA03012045A (es) 2001-07-06 2004-03-29 Teva Pharma Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
AU2003295684A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2007034909A1 (ja) * 2005-09-22 2007-03-29 Kaneka Corporation （３ｒ，５ｒ）－７－アミノ－３，５－ジヒドロキシヘプタン酸誘導体の製造法
WO2007042910A1 (en) * 2005-10-14 2007-04-19 Pfizer Products Inc. Imidazoles and their use as hmg-coa reductase inhibitors
WO2007051065A2 (en) * 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) * 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
US4663373A (en) * 1986-05-01 1987-05-05 Ciba-Geigy Corporation Compositions stabilized with substituted aminoxy silanes
DE3722809A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte

Also Published As

Publication number Publication date
EP0436851A1 (en) 1991-07-17
IT8922767A0 (it) 1989-12-21
JPH04208266A (ja) 1992-07-29

Similar Documents

Publication Publication Date Title
IT1237793B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3770345D1 (de) Inhibitoren von hmg-coa-reduktase.
NO882218L (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
DE3681991D1 (de) Hmg-coa-reduktase-hemmungskoerper.
NO180718C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater
DK0599444T3 (da) Dobbeltvirkende inhibitorer
MC2313A1 (fr) Inhibiteurs d'enzymes
NO178926C (no) Analogifremgangsmåte for fremstilling av farmakologisk aktive pyrimidinforbindelser
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
DE3881373D1 (de) Hmg-coa-reduktase-hemmer.
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
NO882219D0 (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
NO932850L (no) Fremgangsmaate for fremstilling av staal
IT8419141A0 (it) Procedimento per la preparazione dell'estere metilico di alfa-l-aspartil-l-fenilalanina.
ITMI921854A1 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3869282D1 (de) Inhibitoren von hmg-coa-reduktase.
NO901422L (no) Fremgangsmaate for fremstilling av alfa-glucosidase-inhibitorer.
MA21068A1 (fr) Procede de preparation d'une composition a base d'inhibiteur de l'enzyme de conversion de l'angiotensine .
DE69025817T2 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
NO921673D0 (no) Inhibitor av laminin-neurittaktiverende aktivitet
FI103114B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
NO923862D0 (no) Inhibitorer for hmg-coa-reduktase
IE861455L (en) Preparation of hmg-coa reductase inhibitors
SU1277584A1 (ru) 1,1-Ди-[2-(2-фурил)4-оксохиназолинил-3]-этилиден, проявляющий противовоспалительную и анальгезирующую активность

Legal Events

Date Code Title Description
0001 Granted